Received: 5 January 2023
Accepted: 2 April 2023
First Online: 7 July 2023
: Ethics approval was provided by the US Pearl Independent Review Board (IRB) under the Exempt category.
: Not applicable.
: EF has received consulting fees from Rhythm Pharmaceuticals, Inc.; participated in the BBS advisory board for Rhythm Pharmaceuticals, Inc.; and is a clinical investigator for clinical trials of setmelanotide in Bardet-Biedl syndrome for Rhythm Pharmaceuticals, Inc. UGM and CH are employees of Rhythm Pharmaceuticals, Inc. and receive stock or stock options with Rhythm Pharmaceuticals, Inc. MY, AG, and EH are employees of Analysis Group, Inc., which received funding to conduct this study. MLC is a former employee of Analysis Group, Inc., which received funding to conduct this study. JP receives research support from Rhythm Pharmaceuticals, Inc. as a co-investigator for the Setmelanotide Phase 2 Treatment of Obesity in Rare Genetic Disorders (ClinicalTrials.gov Identifier NCT03013543) and as a co-investigator of a study examining unmet medical needs related to obesity in people with Bardet-Biedl syndrome. AMH receives grant funding from the Weston Family Microbiome Initiative and Canadian Institutes of Health Research, is a member of the BBS advisory board for Rhythm Pharmaceuticals, Inc., is a member of the 2021–2022 Somatrogon advisory board for Pfizer, Inc., and is a clinical investigator for trials with Rhythm Pharmaceuticals, Inc. and Levo Therapeutics.